GB2415902A - Ophthalmic eye preparation - Google Patents

Ophthalmic eye preparation Download PDF

Info

Publication number
GB2415902A
GB2415902A GB0414772A GB0414772A GB2415902A GB 2415902 A GB2415902 A GB 2415902A GB 0414772 A GB0414772 A GB 0414772A GB 0414772 A GB0414772 A GB 0414772A GB 2415902 A GB2415902 A GB 2415902A
Authority
GB
United Kingdom
Prior art keywords
preparation
volume
potassium
agent
sodium
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
GB0414772A
Other versions
GB0414772D0 (en
Inventor
Pravin Gordhanbhai Patel
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
ACCUMED Ltd
Original Assignee
ACCUMED Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ACCUMED Ltd filed Critical ACCUMED Ltd
Priority to GB0414772A priority Critical patent/GB2415902A/en
Publication of GB0414772D0 publication Critical patent/GB0414772D0/en
Priority to PCT/GB2005/002537 priority patent/WO2006003383A1/en
Publication of GB2415902A publication Critical patent/GB2415902A/en
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/47—Euphorbiaceae (Spurge family), e.g. Ricinus (castorbean)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
    • A61K36/534—Mentha (mint)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/54—Lauraceae (Laurel family), e.g. cinnamon or sassafras
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/58—Meliaceae (Chinaberry or Mahogany family), e.g. Azadirachta (neem)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/73—Rosaceae (Rose family), e.g. strawberry, chokeberry, blackberry, pear or firethorn
    • A61K36/738—Rosa (rose)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/85—Verbenaceae (Verbena family)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/88—Liliopsida (monocotyledons)
    • A61K36/906—Zingiberaceae (Ginger family)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/88—Liliopsida (monocotyledons)
    • A61K36/906—Zingiberaceae (Ginger family)
    • A61K36/9066—Curcuma, e.g. common turmeric, East Indian arrowroot or mango ginger
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Medical Informatics (AREA)
  • Botany (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Ophthalmology & Optometry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)

Abstract

This invention relates to an ophthalmic eye preparation comprising herbal extracts or their synthetic equivalents and a method for its production. The preparation comprises ocimum sanctum (5-20%), curcuma longa (5-18%), carum copticum (0.5-5%), terminalia belerica (2-7.5%), embilica officinalis (3-10%), terminalia chebula (2-7.5%), camphora officinarum (1-5%), mentha sylvestries (0.5-5%), Eletteria Cardamomum (2-7.5%), santalum album (2-7.5%), santalum rubrum (2-7.5%), azadirachta indica (2-7.5%), vitex negundo (2-7.5%), moringa pterygosperma (2-7.5%), eclipta alba (2-7.5%), boerhaavia diffusa (5-10%) and rosa damascena (5-10%), the preferred amounts of the herbal extracts in percentage by volume being given in brackets.

Description

-1- 2415902
OPHTHALMIC EYE PREPARATION
This invention relates to ophthalmic eye preparations comprising herbal extracts or their synthetic equivalents.
Ophthalmic eye preparations are well known in the art and are generally formulated using pharmaceutical chemicals and drugs for the treatment of eye diseases. In recent years there has been an increasing demand for alternative medical treatment of such eye diseases using herbal formulations. In addition, the extensive use of contact lenses and refractive surgery has created a demand for eye drops that are safer to use in the long term.
The use of synthesised chemicals and drugs as eye drops tends to result in increased side effects and can also cause immunity towards these drugs. The present invention seeks to solve these problems by providing herbal formulations that can be used daily without any significant side effects or adverse interactions with existing medication.
An example of previously known herbal ophthalmic eye preparations is the product "Ophthacare", eye drops sold by the Himalaya Drug Company of India. According to Himalaya's product literature Ophthacare possesses antimicrobial, anti-inflammatory and analgesic qualities and is effective in the management of infective and inflammatory eye disorders. It also claims to relieve congestion and asserts to be beneficial in eyestrain.
The ingredients of Ophthacare are stated to be extracts of Carum copticum (6.00%), Terminalia belerica (6.50%), Emblica officinalis (13.00%), Curcuma longa (13.00%), Ocimum Sanctum (13.00%), Rosa Damascena (11.00%), Cinnamomum camphora (0.50%) and Meldespumatum (37.00%).
S The ophthalmic eye preparations of the present invention
improve on the prior art by comprising a novel
combination of the extracts from 17 herbs, or the synthetic equivalents of the extracts, in therapeutically effective amounts. The preparations result in unexpectedly improved treatment of various eye diseases, dry eye syndrome and the wetting and lubricating of eyes.
The preparations are suitable for use with or without contact lenses. In the process for the production of the preparations using the herbs themselves, the herbs are picked, washed and weighed for processing. The weighed herbs are then enclosed in a high-pressure vessel through which steam is passed, thereby extracting the herbal oils. The steam extraction procedure produces the oils in the form of concentrated oil/water mixtures. The extract is then checked for its composition and sterility.
The herbs used in the preparations, their preferred levels as a percentage by volume and their activity are given below: Ocimum sanctum (Tulsi) anti-inflammatory and anti microbial, 5-20% Curcuma longa (Haridra) anti-inflammatory (comparable to hydrocortisone acetate and phenylbutazone) and anti microbial (comparable to penicillin and streptomycin on gram +ve and gram eve bacteria), 5-18% Carum copticum (Yamani) - anti-bacterial (against Salmonella typhi, Micrococcus pyogenes and Escherichia cold), 0.5-5% Terminalia belerica (Vibhitaka) - antibacterial (against Micrococcus pyogenes and E. colt), 2-7.5% Embilica officinalis (Dhatriphala) - anti-inflammatory and cooling effect, 3-10% Terminalia chebula (Haritaki) - astringent and anti inflammatory, 2-7.5% Camphora officinarum (Kapoor) - anti-bacterial (against several gram +ve and gram eve bacteria), 1-5% Mentha sylvestries (Pudina) - antiseptic and analgesic, 0.5-5% Eletteria Cardamomum (Era) - anti-irritant, 2-7.5% Santalum album (Swet Chandan) - soothing, 2-7.5% Santalum rubrum (Rakta Chandan) - soothing, 2-7.5% Azadirachta indica (Nimba) - antiseptic and anodyne, 2 7.5% Vitex negundo (Nirgundi) - antiseptic and anodyne, 2-7.5% Moringa pterygosperma (Sobhajana) - analgesic, 2-7.5% Eclipta alba (Bhringaraj) - anodyne and antiseptic, 2 7.5% Boerhaavia diffuse (Punarnava) - anti-inflammatory, 5-10% Rosa damascena (Satapatri) astringent and cooling, 5 10% The formulations also include a sequestering or chelating agent, which is preferably present at approximately 0.01 2% by volume. The preferred sequestering agents are ethylenediaminetetraacetic acid (EDTA) and its salts, with the disodium salt, disodium edetate, being especially preferred. - 4
The preparations may also include buffering agents and tonicity adjusting agents. The buffering agents can be used to buffer or adjust the pH of the solution.
Examples of suitable buffering agents include alkali metal salts such as potassium or sodium carbonates, acetates, berates, phosphates, citrates and hydroxides or weak acids such as acetic, boric and phosphoric acids.
Preferably, buffering agents are present at approximately 0.01-2.5% by volume. Examples of tonicity adjusting agents include sodium and potassium chloride, and those materials listed as buffering agents. Tonicity agents may be employed in an amount effective to adjust the osmotic value of the final solution to approximate that of human tears, generally at about 0.01-2.5%.
Additionally, the preparations may include wetting agents or viscosity modifiers. Examples of suitable wetting agents and viscosity modifiers include cellulose derivatives such as cationic cellulosic polymers, hydroxypropyl methylcellulose, hydroxyethylcellulose and methylcellulose, and polyols such as polyethylene glycol, glycerine, polyethylene oxide containing polymers, polyvinyl alcohol and polyvinyl pyrrolidone. Such additives are preferably present at approximately 0.01 1.5% by volume.
Preservatives may also be added to the formulation.
Examples of suitable preservatives include polyhexamethylene biguanide, sorbic acid, benzalkonium chloride and phenyl mercuric nitrate.
The remainder of the composition is water. s

Claims (1)

  1. CLAIMS: 1. An ophthalmic eye preparation comprising a mixture of herbal
    extracts from ocimum sanctum, curcuma longa, carum copticum, terminalia belerica, embilica officinalis, terminalia chebula, camphora officinarum, mentha sylvestries, Eletteria Cardamomum, santalum album, santalum rubrum, azadirachta indica, vitex negundo, moringa pterygosperma, eclipta alba, boerhaavia diffuse and from rosa damascena, or of one or more synthetic equivalent of such extracts.
    2. A preparation as claimed in claim 1, wherein each of the herbal extracts have been obtained by a process comprising the steps of -picking a herb recited in claim 1, optionally washing and weighing it, -placing the herb in a high pressure vessel and . passing steam through the vessel, ë.
    .20 -extracting oil from the herb in the form of a ..
    concentrated oil/water mixture, and ..
    . . -optionally checking the extract for its composition . and sterility. . -
    25 3. A preparation as claimed in either claim 1 or claim .
    . 2, wherein the mixture comprises the following herbal extracts: 5-20% by volume ocimum sanctum 5-18% by volume curcuma longa 0.5-5% by volume carum copticum 2-7.5% by volume terminalia belerica 3-10% by volume embilica officinalis 2-7.5% by volume terminalia chebula 1-5% by volume camphora officinarum 0.5-5% by volume mentha sylvestries 2-7.5% by volume eletteria cardamomum 2-7.5% by volume santalum album 2-7.5% by volume santalum rubrum 2-7.5% by volume azadirachta indica 2-7.5% by volume vitex negundo 2-7.5% by volume moringa pterygosperma 2-7.5% by volume eclipta alba 5-10% by volume boerhaavia diffuse 5-10% by volume rosa damascena.
    4. A preparation as claimed in any one of the preceding claims, wherein the preparation includes a sequestering agent or chelating agent.
    5. A preparation as claimed in claim 4, wherein the sequestering agent or chelating agent is EDTA or one of its salts. . ë
    6. A preparation as claimed in claim 5, wherein the .e EDTA is in the form of its disodium salt. . . A..
    I. 7. A preparation as claimed in any one of the preceding claims, wherein the preparation includes a buffering . 5 agent. . .
    8. A preparation as claimed in claim 7, wherein the buffering agent is an alkali metal salt.
    9. A preparation as claimed in claim 8, wherein the alkali metal salt is potassium or sodium carbonate, potassium or sodium acetate, potassium or sodium borate, potassium or sodium phosphate, potassium or sodium citrate, or potassium or sodium hydroxide.
    10. A preparation as claimed in claim 7, wherein the buffering agent is a weak acid.
    11. A preparation as claimed in claim 10, wherein the weak acid is either acetic acid, boric acid or phosphoric acid.
    12. A preparation as claimed in any one of claims 7 to 11, wherein the buffering agent is present in an amount of 0.01% to 2.5% by volume.
    13. A preparation as claimed in any one of the preceding claims, wherein the preparation includes a tonicity agent.
    14. A preparation as claimed in claim 13, wherein the tonicity agent is an alkali metal salt. .
    15. A preparation as claimed in claim 14, wherein the
    I
    alkali metal salt is potassium or sodium chloride, .
    . . potassium or sodium carbonate, potassium or sodium .. acetate, potassium or sodium borate, potassium or sodium phosphate, potassium or sodium citrate, or potassium or 75 sodium hydroxide. .
    16. A preparation as claimed in any one of claims 13 to 15, wherein the tonicity agent is present in an amount of 0.01% to 2.5% by volume.
    17. A preparation as claimed in any one of the preceding claims, wherein the preparation includes a wetting agent or viscosity modifier.
    18. A preparation as claimed in claim 17, wherein the wetting agent or viscosity modifier is a cellulose derivative or polyol.
    19. A preparation as claimed in claim 18, wherein the cellulose derivative is a cationic cellulosic polymer, hydroxypropyl methylcellulose, hydroxyethylcellulose or methylcellulose.
    20. A preparation as claimed in claim 18, wherein the polyol is polyethylene glycol, glycerine, a polyethylene oxide containing polymer, polyvinyl alcohol or polyvinyl pyrrolidone.
    21. A preparation as claimed in any one of claims 17 to 20, wherein the wetting agent or viscosity modifier is present in an amount of 0.01\ to 1.5% by volume.
    . 22. A preparation as claimed in any one of the preceding claims, wherein the preparation includes a preservative.
    I
    .: . 23. A preparation as claimed in claim 22, wherein the . preservative is polyhexamethylene biguanide, sorbic acid, benzalkonium chloride and phenyl mercuric nitrate. 5
    . 24. A preparation as claimed in any one of the preceding claims, wherein any remainder of the composition is added water.
    25. A process for the production of an ophthalmic eye preparation comprising the steps of: -picking the herbs ocimum sanctum, curcuma longa, carum copticum, terminalia belerica, embilica officinalis, terminalia chebula, camphora officinarum, mentha sylvestries, Eletteria Cardamomum, santalum album, santalum rubrum, azadirachta indica, vitex negundo, moringa pterygosperma, eclipta alba, boerhaavia diffuse and rosa damascena, optionally washing and weighing them, -placing the herbs in a high pressure vessel and passing steam through the vessel, -extracting the herbal oils in the form of concentrated oil/water mixtures, -optionally checking the extract for its composition and sterility, and -formulating the preparation according to the desired composition. - r br 4 b Be. r a. ë ë
GB0414772A 2004-07-01 2004-07-01 Ophthalmic eye preparation Withdrawn GB2415902A (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
GB0414772A GB2415902A (en) 2004-07-01 2004-07-01 Ophthalmic eye preparation
PCT/GB2005/002537 WO2006003383A1 (en) 2004-07-01 2005-06-29 Ophthalmic eye preparation

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB0414772A GB2415902A (en) 2004-07-01 2004-07-01 Ophthalmic eye preparation

Publications (2)

Publication Number Publication Date
GB0414772D0 GB0414772D0 (en) 2004-08-04
GB2415902A true GB2415902A (en) 2006-01-11

Family

ID=32843407

Family Applications (1)

Application Number Title Priority Date Filing Date
GB0414772A Withdrawn GB2415902A (en) 2004-07-01 2004-07-01 Ophthalmic eye preparation

Country Status (2)

Country Link
GB (1) GB2415902A (en)
WO (1) WO2006003383A1 (en)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2905862A1 (en) * 2006-09-20 2008-03-21 Oreal Preparing a topical composition useful to treat oily skin, seborrheic dermatitis, acne, black spots and comedones, comprises percolation of fluid under pressure through vegetable substances containing antibacterial agents
WO2010070664A1 (en) * 2008-11-17 2010-06-24 Laila Pharmaceuticals Pvt. Ltd. Curcuminoids and its metabolites for the application in ocular diseases
JP2012510466A (en) * 2008-12-01 2012-05-10 ライラ ファーマシューティカルズ ピーブイティ．エルティディ． Topical formulations for the treatment of inflammation, skin and mucosal abnormalities and other skin and mucosal diseases

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2901131B1 (en) * 2006-05-22 2008-07-18 Oreal PREPARATION OF FORMULATION FROM PRESSURIZED FLUID, COSMETIC AGENT AND ANIONIC HYDROTROPY, PROCESSING PROCESS EMPLOYING THE SAME
FR2901125B1 (en) * 2006-05-22 2009-02-13 Oreal PREPARATION OF A FORMULATION FROM A PRESSURIZED FLUID, A COSMETIC AGENT AND A HYDROXYL HYDROTROPE, A PROCESSING METHOD EMPLOYING THE SAME
FR2901130B1 (en) * 2006-05-22 2008-07-18 Oreal PREPARATION OF FORMULATION FROM PRESSURIZED FLUID OF COSMETIC AGENT AND CATIONIC HYDROTROPE PROCESSING METHOD EMPLOYING THE SAME
EA017337B1 (en) * 2007-07-19 2012-11-30 Дели Инститьют Оф Фармасьютикал Сайнс Энд Рисерч (Дипсар) A SYNERGISTIC HERBAL COMPOSITION AGAINST CATARACT COMPRISING EXTRACT OF HERBS SELECTED FROM Foeniculum vulgare, Murraya koenigii AND Triphala
IT1395457B1 (en) 2009-05-07 2012-09-21 Sebastiani OPHTHALMIC FORMULATION FOR TREATMENT AND PREVENTION OF PTERIGIOUS
IT1400967B1 (en) 2010-06-15 2013-07-05 St Microelectronics Srl NON-VOLATILE MEMORY DEVICE WITH RECONNECTION CIRCUIT
KR102159343B1 (en) * 2018-08-24 2020-09-23 한국과학기술연구원 A pharmaceutical composition for preventing or treating dry eye syndrome comprising an extract of Terminalia chebula or a fraction thereof and use thereof

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2002353487A1 (en) * 2002-03-27 2003-10-08 All India Institute Of Medical Sciences Herbal ophthalmic formulation for preventing cataract

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
J. Indian Med. Assoc., Vol.83, 1985, Mukherji, R. et al., "Therapeutic efficacy of a new herbal eye drop formulation", pp.237-239 *

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2905862A1 (en) * 2006-09-20 2008-03-21 Oreal Preparing a topical composition useful to treat oily skin, seborrheic dermatitis, acne, black spots and comedones, comprises percolation of fluid under pressure through vegetable substances containing antibacterial agents
WO2010070664A1 (en) * 2008-11-17 2010-06-24 Laila Pharmaceuticals Pvt. Ltd. Curcuminoids and its metabolites for the application in ocular diseases
JP2012508793A (en) * 2008-11-17 2012-04-12 ライラ ファーマシューティカルズ ピーブイティ．エルティディ． Curcuminoids and their metabolites for application to eye diseases
JP2012510466A (en) * 2008-12-01 2012-05-10 ライラ ファーマシューティカルズ ピーブイティ．エルティディ． Topical formulations for the treatment of inflammation, skin and mucosal abnormalities and other skin and mucosal diseases

Also Published As

Publication number Publication date
WO2006003383A1 (en) 2006-01-12
GB0414772D0 (en) 2004-08-04

Similar Documents

Publication Publication Date Title
WO2006003383A1 (en) Ophthalmic eye preparation
US4607038A (en) Ophthalmic pranoprofen compositions
CN106334067B (en) Gynecological gel containing silver ion antibacterial agent, preparation method and application
US10568966B2 (en) Formulation for topical wound treatment
DK2613793T3 (en) NOSE SPRAY
JP6975274B2 (en) Aqueous composition for topical mucosa
JP2020143168A (en) Ophthalmologic or otorhinologic aqueous composition
CA2872210A1 (en) Topical pharmaceutical compositions comprising terbinafide and urea
KR20170036058A (en) Cineole-containing composition for nasal application
US11103464B2 (en) Aqueous composition for ophthalmological use or otolaryngological use
CN114796038A (en) Composition for rapidly removing acne, sterilizing and removing mites as well as preparation method and application thereof
CN104474009A (en) Eye cleaning liquid and preparation method thereof
WO2019125330A2 (en) Nasal decongestant compositions comprising dexpanthenol and sodium hyaluronate
JP5258329B2 (en) Planoprofen-containing aqueous pharmaceutical composition
CN114712375B (en) Application of hydroxy betulinic acid compound in preparation of dermatological medicine
CN106822321B (en) Application of Curcuma water of traumatology in preparing medicine for treating keratosis pilaris
JP2023009258A (en) Ophthalmological preparation
US20170020946A1 (en) Analgesic compositions and methods of use
KR101862628B1 (en) A composition of skin lubicant preparation and the method therefor
CN107149611B (en) Mongolian medicine rhinitis spray and preparation method thereof
CA2529860A1 (en) Ophthalmic composition
CN112535708A (en) Gel composition containing tobramycin and traditional Chinese medicine extract and preparation method thereof
RU2397776C2 (en) Ophthalmologic composition
JP2007291082A (en) Pranoprofen-containing medicinal composition
JPH0250087B2 (en)

Legal Events

Date Code Title Description
WAP Application withdrawn, taken to be withdrawn or refused ** after publication under section 16(1)